Overview

Rituximab (RTX) for Disease Modifying Anti Rheumatic Drug (DMARD) Non-responders in Pakistan: The Pakistan Rituximab Study (PARIS)

Status:
Completed

Trial end date:
2012-12-01

Target enrollment:

Participant gender:

Summary

A study to determine the efficacy and safety of rituximab in Pakistani patients with rheumatoid arthritis (RA) who have been inadequately controlled with standard disease modifying anti rheumatic drugs (DMARDs).

Phase:

Phase 4

Details

Lead Sponsor:

Prof. Abid Z. Farooqi

Collaborators:

Aga Khan University
Fatima Memorial Hospital
Fauji Foundation Hospital, Rawalpindi

Treatments:

Antirheumatic Agents
Rituximab